ResMed Inc. Publishes Transcript of Q2 2026 Earnings Call

Reuters
01/31
ResMed Inc. Publishes Transcript of <a href="https://laohu8.com/S/QTWO">Q2</a> 2026 Earnings Call

ResMed Inc. has published the transcript of its second quarter fiscal year 2026 earnings conference call. The event, held on January 29, 2026, brought together key members of ResMed’s leadership, including the Chief Executive Officer and Chairman of the Board, Chief Financial Officer, and Chief Investor Relations Officer, alongside analysts from leading financial institutions such as Stifel Nicolaus, Mizuho Securities, MST Financial, Citibank, BofA Merrill Lynch, Jefferies, Morgan Stanley, Goldman Sachs, William Blair, and Wells Fargo. During the call, ResMed’s management discussed the company’s continued strong performance and value creation for shareholders. The Chief Executive Officer expressed appreciation for the team’s efforts, stating, “I'm pleased to say we're able to deliver another strong quarter of performance and continue to build value for all of our shareholders.” The call also highlighted ResMed’s global reach, with over 10,000 employees serving people in 140 countries. The management team addressed investor questions and reiterated their commitment to transparent communication, encouraging stakeholders to reach out with further inquiries. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on January 31, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10